CRH

Industry veteran Rob Duke partners with leading private equity firm Kelso & Company to launch Armada Materials; acquires vertically integrated aggregates business near Nashville, TN

Retrieved on: 
Tuesday, October 3, 2023
Professional Services, Other Construction & Property, Finance, Construction & Property, Building Systems, Urban Planning, Landscape, Business development, Building material, Partnership, The Home Depot, EVP, Volunteering, Multimedia, CRH, I-65, Sale, Macquarie Group, Kelso & Company, Acquisition, Management, Armada

Armada Materials, LLC (“Armada” or the “Company”) has been formed to build a leading infrastructure materials and services business through strategic acquisitions.

Key Points: 
  • Armada Materials, LLC (“Armada” or the “Company”) has been formed to build a leading infrastructure materials and services business through strategic acquisitions.
  • The Company was founded by Rob Duke, who will serve as CEO of Armada, along with a group of investors including several industry veterans, and Kelso & Company, L.P. (“Kelso”), a middle-market buyout private equity firm founded in 1980 on the principles of partnership and alignment of interests.
  • Rob brings over twenty years of experience in the construction materials industry with prior leadership roles at CRH, plc and Rinker Materials.
  • “We are eager to support Armada’s growth, both organically and through acquiring top-tier companies like Volunteer” added Matt Edgerton, managing director of Kelso.

Clemson Rural Health Joins Forces with Guardian Research Network to Improve Community Health

Retrieved on: 
Tuesday, October 3, 2023
Database, Partnership, EMR, GRN, Quality of life, Research, CRH, Doctor of Philosophy, Clemson University, Patient, Clemson, Mortality, Health, Rural area, Nursing, Pharmaceutical industry

SPARTANBURG, S.C., Oct. 3, 2023 /PRNewswire/ -- Guardian Research Network (GRN) announces that Clemson Rural Health (CRH), a Clemson University institution dedicated to statewide rural health services initiatives, has joined its nationwide healthcare research consortium. This new partnership will fuel CRH's mission to transform health outcomes in rural communities by conducting and facilitating clinical trials in historically underserved regions. GRN's expansive healthcare database will help CRH bolster community health efforts to reduce premature mortality, decrease preventable hospitalizations and improve overall quality of life for local South Carolina patients.

Key Points: 
  • SPARTANBURG, S.C., Oct. 3, 2023 /PRNewswire/ -- Guardian Research Network (GRN) announces that Clemson Rural Health (CRH), a Clemson University institution dedicated to statewide rural health services initiatives, has joined its nationwide healthcare research consortium.
  • "Clinical trials are critical to realizing our vision to transform health outcomes in rural and underserved communities," said Ron Gimbel, PhD, Clemson professor and director of Clemson Rural Health.
  • According to research conducted by Rural and Remote Health , increasing access to clinical trials reduces health disparities in rural areas.
  • "Partnering with Clemson Rural Health is a significant milestone for GRN," said Bruce Holstien, chairman and CEO at GRN.

Aptose to Present at the Cantor Global Healthcare Conference

Retrieved on: 
Monday, September 18, 2023
CRC, Failure, Symantec Endpoint Protection, TUS, CRH, Clinical trial, European School, AML, Patient, SAN, CR, CFO, CRi, TSX, FLT3, CRP, Conference, Venetoclax, Pharmaceutical industry

SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City.

Key Points: 
  • SAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that the Aptose management team will participate in the Cantor Global Healthcare Conference being held September 26-28, 2023, in New York City.
  • Dr. William G. Rice, Chairman, President and CEO of Aptose, will participate on a panel, Targeted Therapies for AML, and with Mr. Fletcher Payne, CFO of Aptose, will be hosting one-on-one meetings during the conference.
  • To schedule a one-on-one meeting with the Aptose management team, please contact your conference representative.
  • Aptose expects to update these data and release data on additional evaluable patients next month during the European School of Haematology (ESH) meeting in Estoril, Portugal.

Media Advisory: Gary White and Matt Damon to join CEOs and global leaders at UN Global Compact Leaders Summit 2023

Retrieved on: 
Monday, September 11, 2023
Shift, Consultant, Education 2030 Agenda, Sustainable Development Goals, Investment, SVP, Environment, Corruption, Poverty, Chalhoub Group, CFOS, United Nations Office on Drugs and Crime, United, McCormick & Company, UN, IDH, BASF, Entrepreneurship, White, GSK, Water.org, Business, Climate change, Sustainability, BMW, Water, UPM, CFO, Foreign policy, Transparency International, United Nations, FCC, Agropolis Fondation, Economy, PIMCO, CRH, April Group, McCormick, CRH plc, Ten Principles for the Establishment of a Monolithic Ideological System, United Nations Global Compact, United States Department of State, Management, Renewable energy, Crime, Microsoft, Safaricom, Unilever, Shiseido, Responsibility, Nature

Gary White, CEO and Co-founder of water.org and WaterEquity and Matt Damon, Co-founder of water.org, will join Executive Director and CEO of the UN Global Compact, Sanda Ojiambo, CEOs of major corporations and other leaders from the United Nations, governments, civil society and UN Global Compact Local Networks to take stock of business progress on the Sustainable Development Goals (SDGs) at the UN Global Compact Leaders Summit 2023.

Key Points: 
  • Gary White, CEO and Co-founder of water.org and WaterEquity and Matt Damon, Co-founder of water.org, will join Executive Director and CEO of the UN Global Compact, Sanda Ojiambo, CEOs of major corporations and other leaders from the United Nations, governments, civil society and UN Global Compact Local Networks to take stock of business progress on the Sustainable Development Goals (SDGs) at the UN Global Compact Leaders Summit 2023.
  • The converging crises of climate change, a deadly global pandemic, worsening social and economic inequality, unchecked corruption and the devastating consequences of the war in Ukraine have caused unprecedented disruption and global transformation.
  • Alongside the UN General Assembly High-Level Week, this year’s UN Global Compact Leaders Summit will address business leadership during converging crises, the critical role of a principles-based approach, global trends, and tools and partnerships needed to fully achieve the 2030 Agenda.
  • The UN Global Compact will also reveal its twelve new SDG Pioneers — business leaders who are doing an exceptional job to advance the SDGs through the implementation of the Ten Principles of UN Global Compact on human rights, environment, labour and anti-corruption.

Soundcore Capital Partners Announces Rick Barrett as CEO of ACI Holdings Group

Retrieved on: 
Thursday, September 7, 2023
Built environment, Growth, ACI, CRH, Management, Rail transport, Anker Innovations

NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Soundcore Capital Partners, LP ("Soundcore"), a leading New York-based private equity firm specializing in buy-and-build investments in the lower middle-market, is pleased to announce the appointment of Rick Barrett as Chief Executive Officer of ACI Holdings Group, LLC ("ACI").

Key Points: 
  • NEW YORK, Sept. 7, 2023 /PRNewswire/ -- Soundcore Capital Partners, LP ("Soundcore"), a leading New York-based private equity firm specializing in buy-and-build investments in the lower middle-market, is pleased to announce the appointment of Rick Barrett as Chief Executive Officer of ACI Holdings Group, LLC ("ACI").
  • Soundcore initially invested in ACI in July 2022, and since then, the platform has completed three strategic acquisitions, expanding operations and regional footprint.
  • The Soundcore team has proactively hired top-tier talent, implemented improved processes, and provided advanced tools to empower ACI to excel in its endeavors.
  • The platform's commitment to excellence and growth aligns perfectly with my values and expertise," said Rick Barrett.

Aptose to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Retrieved on: 
Thursday, August 24, 2023
CRC, CR, CRi, Clinical trial, FLT3, AML, CRP, Patient, Symantec Endpoint Protection, CRH, Pharmaceutical industry

Among the ten (10) evaluable patients, nine (9) had failed prior venetoclax treatment (Prior-VEN), representing an emerging population with severe unmet medical need.

Key Points: 
  • Among the ten (10) evaluable patients, nine (9) had failed prior venetoclax treatment (Prior-VEN), representing an emerging population with severe unmet medical need.
  • Four (4) of the nine (9) Prior-VEN failure patients had already achieved responses with TUS/VEN (44% CRc).
  • Additionally, two (2) of three (3) patients with mutated FLT3 (67%) achieved responses.
  • Importantly, The TUS/VEN combination continues to be safe and well tolerated.

Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Call, GMP, Drug development, Marketing, Conference call, Intelligence, G&A, Research, CRH, Holocene, Science, Cloud computing, CLIA, Machine learning, Drug discovery, AI, CLI, Conference, Pharmaceutical industry, Cryptocurrency, Video game

The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023.

Key Points: 
  • The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023.
  • Loss per common share for Q2 2023 was $0.98, as compared to $2.89 for the second quarter of 2022.
  • Predictive Oncology recorded revenue of $490,110 in the second quarter of 2023, compared to $371,591 in 2022.
  • The increase was due primarily due to the increase in marketing and business development staff hired after June 20, 2022.

Aptose Reports Results for the Second Quarter 2023

Retrieved on: 
Thursday, August 10, 2023
CRC, TP53, Investment, APS, Symantec Endpoint Protection, Toronto Stock Exchange, CRH, Mutation, Hanmi Pharmaceutical, Acute myeloid leukemia, MDS, US, AML, Documentation, Patient, Indian stock exchange, CR, FLT3, CRi, TSX, FDA, CRP, US FDA, Pharmaceutical industry, Security (finance)

Among fifteen (15) patients dosed with TUS/VEN as of August 1, 2023, ten (10) patients have reached an efficacy evaluable stage.

Key Points: 
  • Among fifteen (15) patients dosed with TUS/VEN as of August 1, 2023, ten (10) patients have reached an efficacy evaluable stage.
  • Equity Investments in Aptose – Today, Aptose announced that it has entered into a binding term sheet with Hanmi Pharmaceutical, Inc. (“Hanmi Pharmaceutical”) of Seoul, South Korea, for an investment of up to $7 million or 19.99 percent ownership interest in Aptose, in two tranches.
  • A monotherapy recommended Phase 2 dose of 80 mg daily was selected and all tuspetinib development paths remain open, including the single arm accelerated path.
  • Plan to discuss strategies for potential future monotherapy accelerated development, doublet phase 2 development, and triplet pilot development (4Q 2023)

WELL Health Reports Record Results for Q2-2023 and Upgrades Guidance for Balance of Year

Retrieved on: 
Thursday, August 10, 2023
Data science, Strategic alliance, Electronic health record, Acquisition, Patient, Investment, Artificial intelligence, WELL Health Technologies, ESG, Quaternary, Anesthesia, EConsult, WELL, Human voice, SEDAR, TSX, Growth, Social, AR, International, Care, MCI, British Columbia Technology Industry Association, Public health, Biophysical environment, Adjustment, Amwell (company), Rare, Multifactorial, Alliance for Natural Health USA, Software as a service, National health insurance, EMR, Bank statement, CRH, Adjusted gross income, EBITDA, AI, Ecosystem, Health, Bookkeeping, Health insurance, Nursing, Medical device, Video game, Pharmaceutical industry, Reinsurance, Wisp, Radar, Computer security

WELL achieved record quarterly revenues of $170.9 million and record Adjusted EBITDA(1) of $27.8 million in Q2-2023.

Key Points: 
  • WELL achieved record quarterly revenues of $170.9 million and record Adjusted EBITDA(1) of $27.8 million in Q2-2023.
  • The Company also almost achieved 1.5 million total patient interactions(2) representing approximately 5.9 million patient interactions on an annualized run-rate basis.
  • We are determined to faithfully support healthcare professionals with the very best technology available which now includes significant investments in AI-based products and services."
  • On July 27, 2023, the Company announced that it has re-branded CRH Medical Corporation as WELL Health USA.

Kura Oncology Reports Second Quarter 2023 Financial Results

Retrieved on: 
Thursday, August 3, 2023
European Hematology Association, Head, CRH, Cancer, Kura, ID, Acute myeloid leukemia, PI3K, Congress, AML, Investigational New Drug, Investment, Patient, KURA, EHA, HNSCC, CR, FLT3, Webcast, Toxic leukoencephalopathy, Research, FDA, Health, Safety, FTI, Disease, Pharmaceutical industry, Video game, Cryptocurrency

ET –

Key Points: 
  • ET –
    SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported second quarter 2023 financial results and provided a corporate update.
  • Research and development expenses for the second quarter of 2023 were $28.2 million, compared to $24.3 million for the second quarter of 2022.
  • General and administrative expenses for the second quarter of 2023 were $11.8 million, compared to $11.1 million for the second quarter of 2022.
  • ET / 1:30 p.m. PT today, August 3, 2023, to discuss the financial results for the second quarter 2023 and to provide a corporate update.